(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 October 2011 (20.10.2011)

PCT

(10) International Publication Number
WO 2011/130195 A1

(51) **International Patent Classification**:
C12P 19/34 (2006.01) *C07H 21/04* (2006.01)

(21) **International Application Number**:
PCT/US2011/032017

(22) **International Filing Date**:
12 April 2011 (12.04.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/323,145 12 April 2010 (12.04.2010) US

(71) **Applicants** *(for all designated States except US)*: **SOMALOGIC, INC.** [US/US]; 2945 Wilderness Place, Boulder, Colorado 80301 (US). **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 2-9, Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-8535 (JP).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **SCHNEIDER, Daniel, J.** [US/US]; 10923 W. 84th Place, Arvada, Colorado 80005 (US). **HISAMINATO, Akihiko** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP). **WAUGH, Sheela** [US/US]; 2763 Odell Drive, Erie, Colorado 80516 (US). **RESNICOW, Daniel** [US/US]; 2954 Shady Hollow West, Boulder, Colorado 80304 (US). **NAGABUKURO, Akira** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP). **ONO, Toshihide** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP).

(74) **Agents**: **KELLOGG, Rosemary** et al.; Swanson & Bratschun, L.L.C., 8210 SouthPark Terrace, Littleton, Colorado 80120 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/130195 A1

(54) **Title**: APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS

(57) **Abstract**: The present disclosure relates generally to the field of nucleic acids and, more particularly, to aptamers capable of binding to β-NGF; pharmaceutical compositions comprising such β-NGF aptamers; and methods of making and using the same.